INTrEPID Data Supports Expanded LVAD Medicare Coverage Request
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart expects CMS to issue by Nov. 12 a coverage decision on left-ventricular assist devices (LVAD) implanted as a destination therapy
You may also be interested in...
WorldHeart Will Learn Fate Of Novacor As Destination Therapy Within 90 Days
WorldHeart may ask FDA's Medical Device Dispute Resolution Panel to re-evaluate the firm's PMA supplement for the Novacor left-ventricular assist device as a destination therapy, according to CEO Rod Bryden
WorldHeart Will Learn Fate Of Novacor As Destination Therapy Within 90 Days
WorldHeart may ask FDA's Medical Device Dispute Resolution Panel to re-evaluate the firm's PMA supplement for the Novacor left-ventricular assist device as a destination therapy, according to CEO Rod Bryden
Who’s In Control? Thoratec, Investigators Discuss Access To NIH-Funded Data
Thoratec is in negotiations with NIH to restrict access to control group data from the REMATCH randomized trial of the HeartMate VE upon the study's completion